Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid

By Ullén Anders   Lennartsson Lena   Harmenberg Ulrika   Hjelm-Eriksson Marie   Kälkner Karl Mikael   Lennernäs Bo   Nilsson Sten  

Acta Oncologica, Vol. 44, Iss. 6, 2005-09 ,pp. : 644-650

Informa Healthcare

Access to resources Recommend Favorite

Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines

By Journé Fabrice   Magné Nicolas   Chaboteaux Carole   Kinnaert Eric   Bauss Frieder   Body Jean-Jacques  

Clinical and Experimental Metastasis, Vol. 23, Iss. 2, 2006-04 ,pp. : 135-147

Springer Publishing Company

Access to resources Recommend Favorite

Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: Possible mechanisms?

By Ugur Ural A.   Avcu Ferit  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 491-492

Informa Healthcare

Access to resources Recommend Favorite

Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?

By Morgan Claire   Wagstaff John  

Acta Oncologica, Vol. 48, Iss. 6, 2009-08 ,pp. : 882-889

Informa Healthcare

Access to resources Recommend Favorite

Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer

By Kuramoto Tomomi   Inagaki Takeshi   Fujii Reona   Sasaki Yumiko   Nishizawa Satoshi   Nanpo Yoshihito   Matusmura Nagahide   Kohjimoto Yasuo   Hara Isao  

International Journal of Clinical Oncology, Vol. 18, Iss. 5, 2013-10 ,pp. : 890-897

Springer Publishing Company

Access to resources Recommend Favorite